Top brokerage firms like Macquarie maintained an outperform rating on Aurobindo Pharma, raising the target price to Rs 1,385. Aurobindo Pharma signed a master service agreement with Merck Sharp & Dohme, leading to a biologics CMO contract with TheraNym.
IDBI Bank Q2 results: Net profit tanks 39% YoY to Rs 2,205 crore; NII dips 49% YoY
IDBI Bank reported a 39% year-on-year profit decline to Rs 2,205 crore in Q2 FY27, impacted by a one-off gain in the previous year. Excluding